Identification of potential COVID-19 main protease inhibitors using structure-based pharmacophore approach, molecular docking and repurposing studies
The current outbreak of novel coronavirus (COVID-19) infections urges the need to identify potential therapeutic agents. Therefore, the repurposing of FDA-approved drugs against today’s diseases involves the use of de-risked compounds with potentially lower costs and shorter development timelines. I...
Main Authors: | Daoud Safa, Alabed Shada J., Dahabiyeh Lina A. |
---|---|
Format: | Article |
Language: | English |
Published: |
Sciendo
2021-06-01
|
Series: | Acta Pharmaceutica |
Subjects: | |
Online Access: | https://doi.org/10.2478/acph-2021-0016 |
Similar Items
-
Molecular Docking of Novel 5-O-benzoylpinostrobin Derivatives as SARS-CoV-2 Main Protease Inhibitors
by: Mohammad Rizki Fadhil Pratama, et al.
Published: (2020-11-01) -
A Multistage In Silico Study of Natural Potential Inhibitors Targeting SARS-CoV-2 Main Protease
by: Eslam B. Elkaeed, et al.
Published: (2022-07-01) -
In silico identification of drug candidates against COVID-19
by: Yifei Wu, et al.
Published: (2020-01-01) -
Computational Repurposing of Mitoxantrone-Related Structures against Monkeypox Virus: A Molecular Docking and 3D Pharmacophore Study
by: Gagan Preet, et al.
Published: (2022-11-01) -
Screening of potential inhibitors targeting the main protease structure of SARS-CoV-2 via molecular docking
by: Xinbo Yang, et al.
Published: (2022-10-01)